Selumetinib
Osteosarcoma
Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03155620CT.gov Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Selumetinib (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | BB |
| (+)-Vincristine | Milton S. Hershey Medical Center | P2 | BB |
| Ipilimumab | Children's National Research Institute | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Etoposide | Eisai Limited | P2 | B |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | B |
| Irinotecan | Milton S. Hershey Medical Center | P2 | B |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
+42 more in the Osteosarcoma cohort
Other indications for Selumetinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P2 | BB · 67 |
| Uveal Melanoma | — | P3 | BB · 65 |
| Metastatic Neoplasm | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Selumetinib in Osteosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/selumetinib-osteosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →